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Arterial hypertension (AH) is one of the most prevalent risk factors for cardiovascular
diseases (CD) and is the main cause of deaths worldwide. Current research establish
that dietary polyphenols may help to lower blood pressure (BP), thus contributing
to the reduction of cardiovascular complications. In addition, the health benefits of
probiotics on BP have also attracted increased attention, as probiotics administration
modulates the microbiota, which, by interacting with ingested polyphenols, controls their
bioavalability. The aim of the present mini-review is to summarize and clarify the effects
of dietary polyphenols and probiotics administration on BP using combined evidence
from clinical and experimental studies, as well as to discuss the current debate in the
literature about the usefulness of this nutritional approach to manage BP. Clinical trials
and experimental studies have demonstrated that consuming dietary polyphenols or
probiotics in adequate amounts may improve BP, ranging frommodest to greater effects.
However, the mechanisms linking probiotic intake and reduced BP levels need to be
further elucidated as a definitive consensus on the link between intake of polyphenols or
probiotics and improvement of AH has not been reached yet.
Keywords: probiotics, hypertension, blood pressure, dietary polyphenols
INTRODUCTION
Arterial hypertension (AH) affects more than 1 billion people and is the major risk factor for CD
(Hedner et al., 2012). The cause of AH has been difficult to identify due to its multi-factorial nature,
which involves genetic and environmental factors. A balanced and healthy diet plays a key role in
themaintenance of the cardiovascular health status, which is a major determinant of lifespan. In the
last decades, in both western and developing countries, the consumption of highly caloric—rich in
fat and carbohydrates—and sodium-rich diets have become predominant, increasing the incidence
of AH (Bjerregaard, 2010; Popkin, 2011).
The regulation of BP is one of the most complex physiological functions and depends on the
integrated actions of cardiovascular, renal, neural and endocrine systems (Corry and Tuck, 1999;
de Brito Alves et al., 2015). In addition, augmentation of proinflammatorymarkers, reactive oxygen
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species and dysfunction in energy metabolism are related to
hypertensive conditions (Carthy, 2014).
Despite the advances in the understanding of the
pathophysiology and pharmacotherapy of AH, interventional
strategies helping to reduce BP levels remain one of the
great problems to be developed. Studies have investigated
the beneficial effect of dietary changes on BP levels and also
identified a BP-lowering activity on different dietary compounds.
The intestine and its microbiota constitute an important
site of interaction with the dietary compounds (Bäckhed et al.,
2004), and in particular polyphenols, whose bioavailability is
dependent on prior metabolization by the microbiota (Ozdal
et al., 2016; Stevens and Maier, 2016). The interaction between
gut microbiota and diet can affect the gut-immune homeostasis,
cell proliferation, metabolism, and intestinal permeability (Ding
et al., 2010). Growing evidence supports the notion that the
gut microbiota plays an important role in the development of
CD and AH (Khalesi et al., 2014; Jose and Raj, 2015), and
dietary compounds might modulate the gut microbiota favoring
or lowering the BP (Buettner et al., 2007; Anhê et al., 2015).
Accordingly, findings have suggested the notion that
dietary polyphenols and probiotic supplementation could help
alleviating AH, by altering the gut microbiota and favoring
an antioxidant activity (Anhê et al., 2015; Gómez-Guzmán
et al., 2015; Grosso et al., 2016), although null and contrary
findings have also been reported (Ras et al., 2013). In the present
mini-review, we summarize the current understanding emerging
from experimental, clinical and epidemiological studies, on how
dietary polyphenols and probiotics intake may help to lower BP
in hypertensive conditions.
DIETARY POLYPHENOLS AND THE
CONTROL OF BP
Polyphenols are a large and heterogeneous family of bioactive
molecules found in numerous food sources. Generally defined
as dietary antioxidants, polyphenols have been established as
bioactive compounds that benefit human health via modulation
of metabolism (Choi et al., 2014). Dietary polyphenols are
mainly classified in catechins (proanthocyanidins), flavonols,
flavanones, ellagitannins, and isoflavones. Studies have
investigated the effects of dietary polyphenols, or their
metabolites supplementation either via administration as
polyphenol-enriched diets, polyphenol extracts from foods
or as administration of specific polyphenolic compounds
(e.g., quercetin, rutin, resveratrol, hesperidin, cinnamon)
(Mendes-Junior et al., 2013; Amiot et al., 2016).
Dietary polyphenols have been shown to exert beneficial
effects on markers for cardiovascular risk factors, including
reduction of BP, improvement of endothelial function and
lowering of plasma lipids. Mechanistically, it has been suggested
that dietary polyphenols can alleviate hypertension through anti-
inflammatory and anti-oxidant effects, and increased oxide nitric
(NO) production (Davinelli and Scapagnini, 2016). The anti-
inflammatory effect is associated with a reduced expression
of the redox-sensitive nuclear factor-kB (NF-κB), while that
the anti-oxidant effect of polyphenols is related to improved
enzymatic activities of superoxide dismutase, catalase and
glutathione peroxidase. In addition, polyphenols participate
in the activation of the redox-sensitive phosphoinositide 3
(PI3)-kinase/Akt pathway, leading to increased formation of
NO (Davinelli and Scapagnini, 2016). Taken together, all
these pathways help to reduce blood pressure in hypertensive
conditions.
Other studies have, however, reached negative or null effects.
These effects have been investigated in several cohorts and
randomized clinical trials (Table 1).
In a small-scale randomized nutritional trial, the
administration of a polyphenol-rich diet (approximately
3000mg polyphenol/day) reduced postprandial triglyceride-rich
lipoprotein plasma concentrations and oxidative stress in study
participants with a high risk of CD (Annuzzi et al., 2014).
The beneficial effects of polyphenol supplementation have also
been demonstrated in the larger PREDIMED (Prevention with
Mediterranean Diet) cohort. In this study, the consumption of
a Mediterranean diet—supplemented with extra-virgin olive oil
or nuts—resulted in reduced incidence of cardiovascular events
(myocardial infarction, stroke, or death from cardiovascular
causes) (Estruch et al., 2013). Within the PREDIMED cohort, a
sub-study on 1139 high-risk participants was performed in which
two different polyphenol-rich diets (based on supplementation
with extra-virgin olive oil or nuts) were randomly assigned.
The increase in polyphenol intake—which was unequivocally
identified as increased total urinary polyphenol excretion—
was associated with decreased inflammatory biomarkers and a
decrease of systolic and diastolic BP (Medina-Remón et al., 2016).
In the Polish population of the non-interventional HAPIEE
cohort (Health, Alcohol and Psychosocial factors In Eastern
Europe), elevated dietary intake of polyphenols was associated
with lower body mass index (BMI), waist circumference
(WC), BP and triglycerides, further suggesting that high
polyphenols intake is inversely associated to metabolic
syndrome and its clinical manifestations (Grosso et al.,
2016). To ascertain whether olive oil polyphenols alleviate AH
independently from the lipid component of olive oil, which
is rich in monounsaturated fatty acids (MUFA), a double-
blind, crossover dietary-intervention study was performed in
which mildly hypertensive women received polyphenol-rich
olive oil (approximately 30 mg/day) in a first dietary period,
and polyphenol-free olive oil in a second dietary period.
Interestingly, only polyphenol-rich olive oil decreased BP and
improved endothelial function, underscoring the specific role of
polyphenols within the olive oil (Moreno-Luna et al., 2012). In
addition, in a randomized, double blind, controlled, crossover
trial, the hypotensive and lipid-lowering capacity have also
been demonstrated for olive leaf extract (Lockyer et al., 2015,
2016).
Although the studies presented above indicate that
administration of dietary polyphenols might contribute to
the control of BP, a definitive consensus has not been reached
yet, as independent investigations did not support the hypothesis
that dietary intake of polyphenols is beneficial to cardiovascular
health (Ras et al., 2013).
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TABLE 1 | Summary of the major studies investigating the relationship between dietary polyphenols intake and blood pressure/cardiovascular health.
Study acronym
(or 1st author)
Study name Number of
participants
Intervention Primary endpoint
observed
Other
parameters
References
PREDIMED Prevention with
Mediterranean diet
7447 2 different
polyphenol-rich diets
Decreased rate of major
cardiovascular events
Decreased systolic
and diastolic blood
pressure
Estruch et al., 2013;
Medina-Remón
et al., 2016
HAPIEE Health, Alcohol and
Psychosocial factors In
Eastern Europe cohort
study
8821
(Polish cohort)
Observational study Amelioration of metabolic
syndrome parameters (Body
mass index, waist
circumference, blood
pressure, triglycerides) in
polyphenol-rich diets
Grosso et al., 2016
EPIC European Prospective
Investigation into Cancer
and Nutrition
20,343
(Greek cohort)
Observational study
with evaluation of a
“Mediterranean Diet
Score”
Inverse correlation between
olive oil intake and arterial
blood pressure
Psaltopoulou et al.,
2004
Ras et al. Effect of polyphenol-rich
grape seed extract on
ambulatory blood pressure
in subjects with pre- and
stage I hypertension
35 Administration of
polyphenol-rich grape
seed extract in a
double-blind, placebo
controlled, randomized,
parallel-group trial
No lowering of blood
pressure in untreated
subjects with pre- and stage
I hypertension
Ras et al., 2013
Mogollon et al. Blood pressure and
endothelial function in
healthy, pregnant women
after acute and daily
consumption of flavanol-rich
chocolate: a pilot,
randomized controlled trial
23 Randomized Controlled
trialof acute and
chronic consumption of
flavanol-rich chocolate
No association with
significant changes in
systolic or diastolic blood
pressure
Mogollon et al.,
2013
RESVERATROL
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a stilbenoid.
Studies demonstrated that resveratrol possess an intrinsic
cancer chemopreventive activity (Jang et al., 1997), and further
interest on this molecule arose with the identification of its
capability to increase lifespan when administered to experimental
organisms including Saccharomyces cerevisiae, Caenorhabditis
elegans, Drosophila melanogaster (Ingram et al., 2006), and mice
(Baur et al., 2006). Furthermore, it was soon documented in
animal models that resveratrol (i) protects from the development
of obesity-dependent metabolic disorders (Fröjdö et al., 2008)
and (ii) can be the molecule responsible for the cardio-protective
effects of red wine (Wu et al., 2011).
Preclinical studies have investigated the effects of resveratrol
administration on cardiovascular health. In spontaneously
hypertensive rats (SHR) and in mice rendered hypertensive by
angiotensin-II injection, resveratrol administration reduced
oxidative stress in the endothelium, improved vascular
function and attenuated AH (Dolinsky et al., 2013). Resveratrol
supplementation to SHR dams during the perinatal period
(from gestation to weaning of the offspring) alleviated the
development of AH in the offspring at the adult age (Care et al.,
2016). These finding have prompted the development of several
small-scale clinical trials evaluating the effects of resveratrol
supplementation on cardiovascular systems.
In some trials, resveratrol supplementation (range 200–300
mg/day) improved insulin resistance, glycemic profile and lipid
metabolism (Wong et al., 2011; Chen et al., 2015). However,
in other studies, 12-week supplementation with 500 mg/day
resveratrol (Faghihzadeh et al., 2015) or 150 mg/day for 4 weeks
(van derMade et al., 2015) did not change metabolic risk markers
related to cardiovascular dysfunction.
A recent meta-analysis of 10 randomized clinical trials
failed to show any benefit of resveratrol supplementation on
cardiovascular risk factors. In particular resveratrol had no effect
on systolic or diastolic BP (Sahebkar et al., 2015). However,
an independent meta-analysis performed on more stringent
adjudication criteria for study quality, including only six studies
comprising a total of 247 subjects, suggested that resveratrol
consumption decreased systolic BP (at the higher administered
doses) while having no significant effects on diastolic BP (Liu
et al., 2015). Given the absence of a clear consensus on the effects
on resveratrol on the control of BP in humans, as opposed to
the clear conclusions in rodent models, the need for larger and
well-designed clinical trials, was solicited by the authors of both
meta-analysis to definitely prove, or reject, a causal link between
resveratrol administration and the control of BP (Novelle et al.,
2015).
QUERCETIN
Quercetin [2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-
chromen-4-one] is a polyphenolic compound belonging to the
class of flavonoids, which is naturally found in apples, berries,
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and red wine (Sigel et al., 1977). Epidemiological data and dietary
analysis indicated that quercetin could contribute to decrease
the risk of coronary heart disease in elderly patients (Hertog
et al., 1993). To test the hypothesis that quercetin reduces BP
in hypertensive patients, a randomized, double-blind, placebo-
controlled, crossover study was performed to test the efficacy of
quercetin supplementation (730mg quercetin/day for 28 days) in
pre-hypertensive and stage-1 hypertensive volunteers. Quercetin
supplementation reduced systolic, diastolic and mean arterial
pressure in stage-1 hypertensive volunteers, while having no
effect on pre-hypertensive participants (Edwards et al., 2007).
More recently, data obtained from hypertensive patients, also
indicated that quercetin supplementation (162 mg/day for 6
weeks) exert cardio-protective effect, with a decrease of 24 h
systolic BP of 3.6 mmHg (Brüll et al., 2015). On the other hand, a
recent similar study in overweight-to-obese adults with AH did
not detect changes in post-prandial BP, nor endothelial function,
upon acute administration of quercetin (54mg in a single dose)
(Brüll et al., 2016). The effects of quercetin administration
are likely dependent on the doses and administration time-
span. A recent meta-analysis of randomized controlled trials
investigating the effects of quercetin on BP support the idea that
quercetin doses greater than 500 mg/day have a significant effect
on the reduction of BP (Serban et al., 2016).
HESPERIDIN
Hesperidin (30, 5, 9-dihydroxy-40-methoxy-7-orutinosyl
flavanone) is an abundant flavonoid found in citrus fruit,
particularly in the peel of oranges and lemon (Sharma et al.,
2015). Reports suggest that hesperidin exerts a cardio-protective
action via its antioxidant and antihypertensive properties
(Wilmsen et al., 2005), as also demonstrated in an ischemic
heart disease model in diabetic rats (Agrawal et al., 2014) and
in SHR (Yamamoto et al., 2008; Ikemura et al., 2012). Over the
last years, a large body of studies in cell culture and animal
models has elucidated the molecular targets and mechanisms
of action of hesperidin. Besides its cardio-protective actions,
hesperidin has also shown anticancer, anti-inflammatory, and
neuroprotective properties (Roohbakhsh et al., 2015). However,
at present, clinical studies regarding the therapeutic effects of
hesperidin have not appeared, and pre-clinical testing in humans
is warranted to confirm the beneficial effects observed in animal
models.
Recently it has been suggested that dietary polyphenols
consumption could help maintain intestinal homeostasis and
metabolic health. In light of recent discoveries, studies have
shown that dietary polyphenols can exert part of their beneficial
action through modulation of the microbiota (Anhê et al.,
2016). For example, it was demonstrated that a polyphenol-rich
cranberry extract prevented obesity and the metabolic syndrome
in diet-induced obesity through prebiotic effect on the gut
microbiota (Anhê et al., 2015). The investigation on whether
dietary polypnehols attenuate BP through beneficial actions on
gut microbiota is a newly developing field and the underlying
mechanisms remain to be elucidated.
EFFECTS OF PROBIOTICS ON BP
The term probiotic means “for life” and it was first used to
describe compounds produced by protozoa to stimulate the
growth of other organisms (Lilly and Stillwell, 1965). Currently,
the term probiotics refers to nonpathogenic microorganisms
(bacteria or yeast) that, when ingested, are capable to reach the
gut in sufficient amounts to confer health benefits (Parvez et al.,
2006). Historically, probiotics derived from dairy products were
the first to be isolated and studied (Tapsell, 2015). However, in the
last decades, potentially probiotic strains from vegetable sources
have also been isolated and their health benefits investigated
(Rivera-Espinoza and Gallardo-Navarro, 2010; Vitali et al., 2012).
Probiotics can be ingested either as supplements or incorporated
in food or beverages in the form of dairy or non-dairy probiotic
products (Jankovic et al., 2010; Vijaya Kumar et al., 2015).
Despite the differences among the quantities of probiotic intake
recommended by American or European Agencies to confer
generic health claims, probiotic intake of around 106–108
CFU/g−1 (or mL−1) or 108–1010 CFU/day (CFU, colony forming
units) have shown to be efficacious (Champagne et al., 2011).
Saccharomyces boulardii is the main nonpathogenic yeast
being used as probiotic. In addition, numerous bacteria
belonging to the Enterococcus, Pediococcus, Bacillus,
Streptococcus, Lactococcus and Propionibacterium genera
are recognized as potential candidates for probiotic status.
It is important to highlight that the Lactobacillus (L.) and
Bifidobacterium (B.) genera constitute the majority of probiotics
found on themarket (Wohlgemuth et al., 2010; Champagne et al.,
2011). Particularly, the lactic acid bacteria L. acidophilus, L. casei,
L. paracasei, L. fermentum, L. reuteri, L. plantarum, L. rhamnosus
and L. salivarius, as well as B. bifidum, B. breve, B. infantis,
B. lactis, B. longum and B. thermophilum are among the main
probiotics species marketed worldwide (Vijaya Kumar et al.,
2015).
The benefits of the ingestion of probiotics by humans
seem to be related to the improvement of the gut microbiota
status, increase of enterocyte’s resistance to pathogens, decrease
or almost total elimination of pathogenic microorganisms
within the intestinal tract, alleviation of nutritional intolerances
(e.g., increased tolerance to lactose), enhancement of macro-
and micro-nutrients bioavailability, and the reduction of the
prevalence of allergies in susceptible individuals (Sharma and
Devi, 2014).
Beneficial effects on intestinal permeability to
macromolecules, including lipopolysaccharides and on gut
inflammation are also considered as major mechanisms
conferring health benefit to probiotics (Cani, 2014). A recent
study in a germ-free mouse model has also shown that
administration of probiotics belonging to the Lactobacillus genus
may alleviate the negative effects of chronic under-nutrition on
postnatal growth (Schwarzer et al., 2016).
Interestingly, experimental and clinical reports have
demonstrated that improvement of the gut microbiota though
probiotic supplementation might positively help in reducing BP
in the hypertensive conditions (Ettinger et al., 2014; Jose and Raj,
2015; Mell et al., 2015).
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Despite these findings, other reports has shown that the
probiotic supplementation did not induce any significant
alterations in BP, heart rate (HR) or cardiovascular risk
markers, such as total cholesterol, low-density lipoprotein, pro-
inflammatorymarkers (Barreto et al., 2014;Mahboobi et al., 2014;
Ivey et al., 2015).
EXPERIMENTAL FINDINGS
By using a hypertensive rat model treated with nitro-L-
arginine methyl ester (L-NAME), it was demonstrated that
the supplementation of fermented blueberries (very rich in
polyphenols) containing L. plantarum (2 g/day for 4 weeks,
containing 109 CFU) reduced systolic (by approximately 45%)
and diastolic (by approximately 45%) BP in hypertensive animals
(Ahrén et al., 2015). Mechanistically, it has been suggested that
fermentation of blueberries by L. plantarum could reduce BP
trough a mechanism involving a nitric oxide (NO)-dependent
pathway (Ahrén et al., 2015). However, another study showed
that adding probiotics to a blueberry-enriched diet did not
enhance, and actually might have impaired the anti-hypertensive
effect of blueberry consumption (Blanton et al., 2015).
In SHR, long-term administration of L. fermentum or
L. coryniformis plus L. gasseri (3.3 × 1010 CFU/day, for 5 weeks)
similarly induced a progressive reduction in the systolic arterial
pressure without significant modifications of the HR (Gómez-
Guzmán et al., 2015). This finding was linked to improved
endothelial function, reduced vascular oxidative stress and
decreased vascular inflammation in the aorta of SH rats (Gómez-
Guzmán et al., 2015). Interestingly, recombinant L. plantarum
expressing angiotensin converting enzyme inhibitory peptide was
effective in the diminution of BP in SHR. This finding was linked
to increased levels of NO, as well as decreased levels of endothelin
and angiotensin II in plasma, heart, and kidney in SHR (Yang
et al., 2015).
The treatment with the probiotic formulation termed VSL#3
(Streptococcus thermophilus, B. longum, B. breve, B. infantis,
L. acidophilus, L. plantarum, L. casei, L. bulgaricus) prevented
endothelial dysfunction and improved vascular oxidative stress
most likely by reducing bacterial translocation and the local
angiotensin system in the mesenteric artery of rats with portal
hypertension (Rashid et al., 2014). Another mechanism involved
in the antihypertensive effect of probiotics is the production of
bioactive peptides with angiotensin converting enzyme (ACE)
inhibitory properties during the fermentation process (Thushara
et al., 2016). ACE inhibition, in turn, lowers the synthesis of
angiotensin II, which result in attenuation of vasoconstriction
and blood pressure.
CLINICAL FINDINGS
Initial clinical testing of the hypothesis that probiotics could
reduce BP has been performed in small-scale, double blind,
placebo-controlled studies. For example, supplementation
of the diet with L. plantarum for 6 week in a population
of smokers of both genders resulted in reduced systolic
BP, improvement of metabolic alterations and attenuated
generation of reactive oxygen species (Naruszewicz et al.,
2002). Nevertheless, in an investigation in postmenopausal
women with metabolic syndrome, a 14 days supplementation
with fermented or non-fermented milk supplemented with
L. plantarum, did not result in an improvement of systolic or
diastolic BP. However, a significant reduction in total cholesterol,
low-density protein cholesterol, glucose, homocysteine and
inflammatory biomarkers was observed (Barreto et al.,
2014), although this was not associated to reduced arterial
BP, perhaps because of the short duration of the study.
Similarly, administration to obese hypertensive patients of an
hypocaloric diet (1500 kcal/day), supplemented with cheese
containing the probiotic L. plantarum showed a remarkable
reduction of body mass index associated with decrease of
BP when compared to a control group receiving the same
diet without probiotic supplementation (Sharafedtinov et al.,
2013).
In a randomized double-blind clinical trial on type 2
diabetic volunteers, the supplementation with probiotic
soymilk (containing L. planetarium A7) did not change the
anthropometric parameters (represented by body mass index
and waist to hip ratio), however, it reduced both systolic and
diastolic BP (Hariri et al., 2015).
On the other hand, a 6-weeks randomized, controlled, parallel,
double blind, factorial study performed in overweight men
and women, demonstrated that consumption of L. acidophilus
and B. animalis (at a dose of 3 × 109 CFU/day) did
not significantly alter BP, HR, total cholesterol, lox density
lipoprotein, high density lipoprotein, or triglycerides (Ivey et al.,
2015). Similarly, another double-blind randomized controlled
study, found that L. acidophilus and B. bifidum supplementation
did not reduce systolic or diastolic BP in healthy adults
with hypercholesterolemia (Rerksuppaphol and Rerksuppaphol,
2015). These findings suggest that the choice of an appropriate
strain, as also the optimal dosage is crucial to achieve ideal
beneficial effects from probiotics.
CONCLUSION
The experimental and clinical findings summarized in this review
suggest that dietary polyphenols or probiotic consumption may
reduce BP and improve cardiovascular risk markers. Future
studies investigating the effects of different polyphenolic
compounds and probiotics, optimal dosage, intervention times,
and studies on the underlying molecular mechanisms leading to
improved control of BP are recommended to clarify the beneficial
effects of dietary polyphenols and probiotics on AH. In addition,
studies are needed to investigate the combined supplementation
with dietary polyphenols and probiotics on the BP
levels.
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